Introduction
The tumor suppressor p53 plays a critical role in mediating cell cycle arrest and/or apoptosis following exposure to stress stimuli (reviewed in Burns and ElDeiry, 1999; Gottlieb and Oren, 1998; Levine, 1997; Sionov and Haupt, 1999) . Cell cycle arrest induced by p53 has been shown to be directly related to its ability to bind DNA and to activate transcription in a sequencespeci®c manner mainly through the induction of the cyclin dependent kinase inhibitor p21 (Brugarolas et al., 1995; Chan et al., 2000; Deng et al,. 1995; el-Deiry et al., 1993) . The mechanism by which p53 mediates apoptosis is not well understood, and neither is it clear whether the function of p53 in transcriptional activation is related to its function in apoptosis (Bates and Vousden, 1999) . Previous reports have provided indirect evidence that p53-mediated apoptosis and transactivation are uncoupled (Bennett et al., 1998; Caelles et al., 1994; Wagner et al., 1994) . However, many other reports suggest that trans-activation by p53 is required to mediate apoptosis and in some cases through transcriptional activation of the pro-apoptotic protein Bax (for review see Bates and Vousden, 1999) . Thus far no direct genetic evidence exist that a function distinct from the transactivation function of p53 is required to induce apoptosis. To gain insight into the mechanism by which p53 induces apoptosis; temperature sensitive (ts) p53 alleles were introduced by retroviral infection into human carcinoma cell lines. Conversion of alanine 138 of human p53 to valine creates a temperature sensitive p53 mutant analogous to the Val135 mutant the murine p53 that assumes its wild type conformation only at the permissive temperature (Michalovitz et al., 1990) . We have also generated a triple p53 mutant in which, in addition to Val138 mutation, amino acids leucine 22 (Leu22) and tryptophan 23 (Trp23) were converted to glycine and serine respectively. The Gln22, Ser23 mutant of p53 was shown to be inert for transactivation (Lin et al., 1994) . The use of a temperature sensitive mutant of p53 enabled us to generate stable cell lines that overexpress p53 and to study p53 function in these cells without an immediate cytotoxic or cytostatic eect. Cells expressing Val138 mutant undergo cell cycle arrest in G1 and G2/M phases of cell cycle upon shift to the permissive temperature. The triple mutant Val138, Gn22, Ser23, however, does not elicit cell cycle arrest. In the colon carcinoma cell line HCT116, the (Val138, Gln22, Ser23) p53 elicits apoptosis at the permissive temperature whereas Val138 does not. The inability of wild type p53 to elicit apoptosis is restored in HCT116 cells de®cient of p21. However, the transactivationdefective p53 mutant is also a more eective inducer of apoptosis even if p21 is deleted. The ability to repress Bcl-2 expression is retained in the Gln22, Ser23 mutant and may explain, at least in part, its ability to elicit apoptosis. Taken together these results suggest that the transactivation function of p53 is not only dispensable but also inhibitory for apoptosis.
Results
Analyses of wild type and mutant p53 in PC-3 prostate carcinoma cells
The human ts p53 allele (Val138) was constructed by changing the alanine at position 138 to valine in analogy to the valine 135 mutation in the murine ts p53 allele (Michalovitz et al., 1990) . The cDNAs were introduced into pMV12 retroviral vector to generate amphotropic retroviruses as described in Materials and methods. Following infection of PC-3 cells, which are null for endogenous p53 (Isaacs et al., 1991) , several hundred hygromycin-resistant clones expressing the ts p53 allele were pooled and maintained as a polyclonal cell line. In addition, several individual clones were isolated. Expression of p53 in the pool and in two independent clones is shown in Figure 1a , lanes 3 ± 8 and Figure 1b , lanes 3 ± 8. To con®rm that the infected cells express a ts p53 allele, p53 protein was immunoprecipitated from lysates of cells grown at the restrictive (378C) and permissive (328C) temperatures with antibodies (PAb 240; Gannon et al., 1990 ) that recognize the mutant or a pan-speci®c antibody (PAb 1801; Figure 1c ). In addition, we have demonstrated the induction of two p53 target genes, hdm2, the human homologue of mdm2, (Wu et al., 1993) and p21 (el-Deiry et al., 1993; Harper et al., 1993) , upon shift to the permissive temperature (Figure 2 ), indicating that this is a functional ts p53 allele. Levels of both hdm2 and p21 mRNA, detectable within 30 ± 60 min, were induced approximately 40-fold 8 h after the temperature shift (Figure 2a) . Induction of hdm2 and p21 protein expression, 24 h after temperature shift, was demonstrated by Western analysis (Figure 2b,c) . Induction of both proteins was ®rst detectable approximately 4 h after temperature shift (not shown).
The ts p53 allele was further mutated to construct a triple mutant (Val138, Gln-22, Ser23_ that contains two additional mutations (Leu22Gln and Trp23Ser) which were previously shown to abolish transcriptional activation by p53 (Lin et al., 1994) . Expression of the triple mutant in a pool and two independent clones is shown in Figure 1a lanes 9 ± 14. Antibodies directed against the carboxy terminus of p53 detect the triple mutant protein but the triple mutant is not by an antibody that recognizes an epitope at the amino terminus ( Figure 1b, lanes 9 ± 14) . In contrast to the (Val138) p53 mutant, the (Val138, Gln22, Ser23) p53 triple mutant was not able to induce the p53 target genes, p21 and hdm2, following temperature shift (Figure 2b,c) .
The ability of the two p53 mutant alleles to elicit cell cycle arrest was analysed by¯ow cytometry (Figure 3a, b) and BrdU incorporation ( Figure 3c ). As shown in Figure 3 , after the cells expressing the (Val138) p53 mutant were shifted to the permissive temperature, cell cycle progression was arrested in both G1 and G2/M phases of cell cycle with a very small percentage of cells in S phase. Cells expressing the triple mutant, however, were not arrested and exhibited a pro®le similar to the parental cells. The reduction seen in the S phase 2) and in PC-3 cells infected with retroviruses expressing Val138 p53, pool (lanes 3 and 4), clone 1 (lanes 5 and 6) and clone two (lanes 7 and 8), or Val138, Gln22, Ser23 p53, pool (lanes 9 ± 10), clone 1 (lanes 11 and 12), and clone 2 (lanes 13 and 14). Odd-numbered lanes are extracts from cells incubated at 378C, even-numbered lanes are extracts from cells incubated at 328C. p53 expression was detected with carboxy-terminal domain-speci®c monoclonal antibody PAb421 (Ab-4, Oncogene Science). C.1, clone 1; c.2, clone 2. (b) Western analysis of p53 expression as described in (a), using an amino-terminal domain-speci®c monoclonal antibody to amino acids 21 ± 25 (DO-1, Santa Cruz Biotech. Inc.). (c) Immunoprecipitation of wild type and mutant p53 from retrovirally infected PC-3 cells. Parental PC-3 cells (lanes 1, 4) and Val138 p53-clone 1 cells (lanes 2, 3, 5, 6) were incubated at the indicated temperatures and p53 protein was immunoprecipitated using pan-speci®c antip53 antibody (PAb1801; lanes 1 ± 3) or mutant-speci®c anti-p53 antibody (PAb240; lanes 4 ± 6). Blotted p53 was detected with PAb240 anti-p53 antibody Figure 2 Expression of p21 and hdm-2 mRNAs and proteins following temperature shift of parental PC-3 cells and PC-3 cells expressing (Val138) p53 or (Val138, Gln22, Ser23) p53. (a) RNAse protection assay demonstrating rapid induction of p21 and hdm-2 mRNA levels following temperature shift in Val138 p53-clone 1 cells. Lanes 1, 10; pBR322/MspI molecular size markers; lanes 2 ± 7 and 11 ± 16: RNA from various times after temperature shift of clone 1 cells, as indicated in hours. Lanes 8, 9 and 17, 18: 0 and 8 h after temperature shift of parental PC-3 cells. The positions of the protected p21 or hdm-2 riboprobes and b2 microglobulin riboprobe are indicated. Quanti®cation of normalized mRNA levels is presented in the graph. Each point on the graph represents the mean of two independent experiments. (b) Western analysis of p21 levels in PC-3 cells expressing Val138 p53 or Val138, Gln22, Ser23 p53, 0 h (odd-numbered lanes) and 24 h (even-numbered lanes) after shift to permissive temperature. Loading order is as in Figure 1a . (c) Western analysis of hdm-2 level in PC-3 cells expressing Val138 p53 or Val138, Gln22, Ser23 p53, 0 or 24 h after shift to permissive temperature. Lanes are as in Figure 1a distribution and decrease in BrdU incorporation at 328C of cells expressing the p53 triple mutant and the parental cell (Figure 3b ,c) is probably a result of a slower growth rate at 328C. These results con®rm that the ability of p53 to induce cell cycle arrest is tightly linked to transcriptional activation. It is likely that G2 arrest results from highly induced levels of the cyclindependent kinase inhibitor p21 as previously shown (Chan et al., 2000; Harper et al., 1993 and see below) .
The Gln22, Ser23 mutant of p53 elicits more apoptosis than wild type p53
Although PC-3 cells that stably express wild type p53 undergo cell cycle arrest we were unable to demonstrate p53-mediated apoptosis in these cells (data not shown). We therefore utilized the colon carcinoma cell line HCT116. The Val138 and the Val138, Gln22, Ser23 mutants of p53 were stably expressed in HCT116 cell as described above for the PC-3 cells except that the pMV720 viral vector was used instead of pMV12. Following infection cells were selected for puromycin resistance. Cell cycle analysis recapitulated the results obtained with the PC-3 cells showing that the Val138 induces cell cycle arrest at 328C as manifested by a signi®cant decrease in S phase whereas the triple mutant Val138, Gln22, Ser23 does not elicit cell cycle arrest (Figure 4a) . Accumulation of cells with less than 2N DNA content (sub G1) indicative of apoptotic cells is evident in HCT116 expressing the triple mutant at the permissive temperature (Figure 4a ). The relatively large number of cells in G2 phase is likely because a large fraction of G1 cells undergo apoptosis and are in the sub G1 phase. To further quantify apoptosis in these cells, the cells were ®xed and stained with DAPI, and cells with condensed or fragmented nuclei were Oncogene Transcriptional activation of p53 and apoptosis JM Kokontis et al scored as apoptotic as was previously described (Kennedy et al., 1997) . As shown in Figure 4b the Val138 mutant does not elicit apoptosis at 328C consistent with previous results (Polyak et al., 1996) . In contrast to cells expressing Val138 mutant, signi®cant induction of apoptosis was observed in Val138, Gln22, Ser23 mutant expressing cells when shifted to the permissive temperature (Figure 4) .
The reduced ability of wild type p53 to elicit apoptosis is restored in HCT116 cells that are null for p21 but the Gln22Ser23 mutant is still a more potent inducer of apoptosis in these cells
Previous experimental evidence showed that the apoptotic function of p53 is restored in HCT116 cells in which p21 gene was deleted by homologous recombination (Polyak et al., 1996) . We therefore introduced the Val138 and Val138, Gln22, Ser23 mutants into the HCT116 cells that are null for p21. Consistent with previous results (Polyak et al., 1996) the Val138 mutant in its wild type conformation (at 328C) did not elicit cell cycle arrest in these cells (Figure 5a ) whereas apoptosis was induced upon shift to the permissive temperature (Figure 5a ). However, the Val138, Gln22, Ser23 mutant elicited signi®cantly more apoptosis in these cells than the Val138 (Figure  5b) . Thus, the results strongly suggest that an additional trans-activated target of p53 besides p21 negates its apoptotic function.
The ability of p53 to induce apoptosis in HCT116 cells is not dependent on trans-activation of Bax Thus far, the only trans-activated p53 gene that is directly linked to the classical apoptotic cascade is the pro-apoptotic Bcl-2 family member Bax. Bax was shown to be induced by p53 in various experimental systems and was suggested to be the mediator of p53-induced apoptosis (Miyashita et al., 1994b; Miyashita and Reed, 1995) . However, as shown in Figure 6a , we have been unable to demonstrate any change in Bax levels in either PC-3 or HCT116 cells expressing the ts mutants upon shift to the permissive temperature, whereas p21 and hdm2 induction is clearly evident (Figures 2 and 6b ).
Bcl-2 expression is down-regulated by both Val138 p53 and by Val138, Gln22, Ser23 p53 in HCT116 cells
The Bcl-2 gene was reported to be down-regulated by p53 (Harn et al., 1996; Miyashita et al., 1994a) . The repression of Bcl-2 expression of p53 was attributed to the ability of p53 to elicit apoptosis through repression of transcription. Because the trans-repression ability of p53 may be intact in the transactivation defective mutant it is possible that this mutant mediates apoptosis through repression of Bcl-2 expression. We therefore examined the steady state levels of Bcl-2 protein upon shift to the permissive temperature. As shown in Figure 7 , both wild type p53 and the Gln22, Ser23 mutant signi®cantly decreased the steady state level of Bcl-2. These results suggest that the ability of p53 to repress gene expression is left intact. The down-regulation of Bcl-2 by the Gln22, Ser23 mutant and may explain, at least in part, the ability of this mutant to elicit apoptosis (see Discussion).
Discussion
The pathway of p53-mediated apoptosis has been dissected for several years but the exact mechanism by which p53 exerts its apoptotic function remains unresolved. Much experimental evidence points to the sequence-speci®c trans-activation by p53 as a major mechanism for p53-mediated apoptosis. The current view is that for full apoptotic response, transcriptional activation dependent and independent functions of p53 are required. In this study we challenge the view that p53-mediated apoptosis is largely dependent on transcriptional activation. Previous results using inhibitors of protein synthesis and transcription provided indirect evidence that de novo gene expression and transcriptional activation induced by p53 are not required to execute its apoptotic function (Bennett et al., 1998; Caelles et al., 1994; Wagner et al., 1994) . However, the requirement of p53 induced gene expression for p53-mediated apoptosis remains under debate. First, it was shown that although the transactivation of p21 by p53 is not required and is inhibitory for p53-mediated apoptosis the trans-activation function of p53 is still required to exert its apoptotic function (Attardi et al., 1996) . Second, several p53-induced target genes have been implicated in execution or sensitization to apoptosis. These include the pro-apoptotic Bcl2 family member, Bax (Miyashita et al., 1994a; Miyashita and Reed, 1995) , the death receptor Fas (Owen-Schaub et al., 1995) , and Killer/DR5 (Wu et al., 1997) , the IGF binding protein, IGF-BP3 (Buckbinder et al., 1995) and genes such as PIG3 that may induce oxidative stress (Polyak et al., 1997) .
In this study we have provided evidence that the trans-activation function of p53 not only is not required to exert apoptosis but also inhibits apoptosis. We showed that overexpression of wild type p53 without an additional apoptotic insult induces only cell cycle arrest and no apoptosis whereas a mutant that is inert for trans-activation induces apoptosis and no cell cycle arrest. The trans-activation function of p53 is required to induce cell cycle arrest mainly because of the induction of p21 as cells that are null for p21 are not arrested by p53. The induction of p21 by wild type p53 antagonizes its apoptotic function and therefore, as shown in Figure 5b , p53 restores its apoptotic function in p21 null cells. However, the trans-activation de®cient mutant is more potent than wild type p53 even in a p21 null background suggesting that additional trans-activated targets of p53 negate its apoptotic function. One possible explanation for these results is that trans-activation of hdm2 by p53 is also inhibitory to its apoptotic function because HDM2 protein then binds to p53 and reduces its level by mediating its degradation (Haupt et al., 1997) . Because the ability of Gln22, Ser23 mutant to bind HDM2 is impaired (Lin et al., 1994) this mutant should be less susceptible to degradation, although we did not observe any signi®cant change in the steady state levels of wild type versus Gln22, Ser23 proteins (Figure 1a) . Thus, the possibility that wild type p53 induces other genes that antagonize or attenuates apoptosis cannot be excluded. The anti-apoptotic eect of p21 on p53-mediated apoptosis could be explained by the induction of cell cycle arrest, as cell cycle arrest in general antagonizes apoptosis, but speci®c anti-apoptotic functions were also attributed to p21 (Cardone et al., 1998) .
Previous studies with the Gln22, Ser23 mutant also showed that it could elicit apoptosis although to a lesser extent than wild type p53. This was attributed to residual transactivation capability of this mutant (Zhu et al., 1998 (Zhu et al., , 2000 . However, all our attempts showed that in the cell system used in these studies the Gln22, Ser23 mutant is inert in trans-activation. Thus, although we cannot completely exclude that this mutant can retain ability to trans-activate certain genes, we believe that in cells in which this mutant is capable of transactivation its ability to induce apoptosis is impaired.
We propose (as schematically illustrated in Figure 8 ) that the initial response of p53 to an apoptotic insult is activation of genes that attenuate both cell cycle and apoptosis. This may provide the cells an opportunity to repair the damage. However, if the damage cannot be repaired and/or the apoptotic insult is maintained, then p53 can rapidly induce cell death through repression of transcription and/or through a mechanism that is transcription-independent. One possible transcriptionindependent mechanism is through facilitating the translocation of Fas from Golgi to plasm membrane (Bennett et al., 1998) . A large number of p53-repressed genes have been discovered (Polyak et al., 1997) and repression of transcription could be also playing a major role in the execution of apoptosis by p53. For example, E1B 19k, and Bcl2 that block p53-mediated apoptosis were also reported to inhibit p53-mediated trans-repression (Sabbatini et al., 1995; Shen and Shenk, 1994; Yew et al., 1993) . The gene encoding the microtubuleassociated protein MAP4, a protein that seems to have a role in execution of apoptosis, is repressed upon induction of p53-mediated apoptosis (Murphy et al., 1996) . Interestingly, the decrease in MAP4 is also inhibited by E1B 19k (Murphy et al., 1996) . The Bcl-2 gene itself was also reported to be inhibited by p53. Our results (Figure 7 ) strongly suggest that the mutant Gln22, Ser23 p53 retains the ability to down-regulate Bcl-2 expression and this may explain, at least in part, the ability of this mutant to elicit apoptosis. The reduction in Bcl-2 level may be sucient to elicit apoptosis by the trans-activation de®cient mutant but not by wild type p53 because the trans-activation function of wild type p53 can negate apoptosis. The region implicated in transrepression by p53 is a proline rich region between amino acids 64 and 92. Interestingly this region was also implicated in apoptosis and in non-sequence speci®c transactivation by p53 of the PIG3 gene that is involved in reactive oxygen species production. Thus it is likely that the function of the proline rich region was left intact in the Gn22, Ser23 mutant.
Regardless of the mechanism by which the Gln22, Ser23 p53 mutant is eliciting apoptosis, it might be a better candidate than wild type p53 in gene therapy and drug development strategies that seek to restore wild-type p53 activity in cancer cells.
While this manuscript was under review, it was reported that in mouse ES cells and thymocytes replacement of wild type p53 allele with the mouse equivalent of Gln22, Ser23 mutant renders the cells resistant to DNA damage-induced apoptosis (Chao et al., 2000) . Two possible explanations could account for this discrepancy: First, it is possible that the ability of 22, 23 mutant to elicit apoptosis is either restricted to human cells or it is cell type speci®c. Second, and the more likely explanation, is that in primary normal cells the high stable level of 22, 23 mutant (Chao et al., 2000) cannot be tolerated and can kill the cells unless other events have occurred to make the cells resistant to cell death. Therefore, it is possible that during generation and selection of the ES cells additional mutations may have been acquired by the cells to compromise the apoptotic activity of this p53 mutant in order to tolerate its expression.
Materials and methods

Construction of retroviral vectors
Alanine 138 of the wild type human p53 protein was converted to valine by PCR-mediated site-directed mutagenesis. The Val138, Gln22, Ser23 triple mutant p53 cDNA was constructed by ligating a AvaII-digested 400 bp N-terminal fragment generated by PCR from a human Gln22, Ser23 p53 cDNA (Lin et al., 1994) (kindly provided by Dr A Levine) to an AvaII-digested (Val138) p53 fragment. PCR products were sequenced to verify accuracy of ampli®cation. The p53 cDNAs were then inserted into pMV12 or pMV720 retroviral vectors for the generation of amphotropic retrovirus in the PA317 or fNX-ampho packaging cell lines. The EcoRI ± ClaI fragment of pMV7 containing the thymidine kinase promoter and neomycin resistance gene was replaced with the EcoRI ± ClaI fragment of pBABEpuro containing the SV40 early promoter and puromycin resistance gene to generate the pMV720 vector. Generation of retrovirus, infection of cells and selection for hygromycin or puromycin resistant clones were performed as described previously (Kennedy et al., 1997; Wagner et al., 1993 Wagner et al., , 1994 .
Cell culture PC-3 human prostate carcinoma cells were maintained on Dulbecco's Modi®ed Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). HCT116 human colon carcinoma cells, generously provided by B Vogelstein, were maintained on McCoy's 5A medium supplemented with 10% FBS.
RNA and protein analyses
For RNAse protection assay of p21 mRNA, an antisense 32 Plabeled riboprobe, which protects a 419 base p21 mRNA fragment, was synthesized with T7 RNA polymerase and PstI-digested p21 inserted into pBluescript II. For RNAse protection assay of hdm-2 mRNA, an antisense 32 P-labeled riboprobe, which protects a 367 base C-terminal hdm-2 mRNA fragment, was synthesized with T3 RNA polymerase and SalI-digested hdm-2 inserted into pBSII. As an internal control, an antisense 32 P-labeled riboprobe which protects a 150 base b 2 -microglobulin mRNA fragment was included in hybridizations. Conditions for hybridization and RNAse digestion were described previously (Wagner et al., 1992) . Conditions for Western analysis antibody incubation and complex visualization were performed as described previously (Wagner et al., 1994) except that 12.5% SDS-polyacrylamide gels were used for p21 analysis. p21 and hdm-2 proteins were detected by polyclonal rabbit anti-p21 (Pharmingen) or monoclonal mouse anti-mdm-2 (Ab-1, Oncogene Science). Immunoprecipitation was performed under non-reducing conditions as described previously (Wagner et al., 1994) .
Cell cycle analysis
After 48 h at 32 or 378C, subcon¯uent cells were trypsinized and ®xed in 70% ethanol in PBS. Cells were incubated with RNAse A and stained with 100 mg/ml propidium iodide. Cell cycle pro®les and distributions were determined by¯ow cytometric analysis of 10 4 cells using the LysisII program on a FACScan¯ow cytometer (Becton-Dickenson). BrdU incorporation and immuno¯uorescent staining of PC-3 cells grown on glass cover slips were performed according to the protocol furnished by the supplier (Boehringer-Mannheim).
Apoptosis assays
Apoptosis of HCT116 cells was measured by direct microscopic counting of apoptotic nuclei after ®xation and staining with 4',6-diamidino-2-phenylindole (DAPI). Cells were plated on 6-well culture dishes at 10 5 cells/well and incubated for 24 h at 378C. Then medium was replaced and one set of plates was shifted to 328C while one set remained at 378C. Incubation continued for an additional 48 h, when cells were ®xed by the addition of 1 ml of 37% formalin to each well. After 15 min, cells were rinsed four times with phosphate-buered saline (PBS) and stained with a 1 mg/ml solution of DAPI for 5 min. After four more washes with PBS, cells were mounted in Aqua-mount and examined with a¯uorescent microscope.
